Top

Published in:

01-01-2021 | Idiopathic Pulmonary Fibrosis | Review and Perspectives

Molecular approach to the classification of chronic fibrosing lung disease—there and back again

Authors: Stijn E. Verleden, Peter Braubach, Mark Kuehnel, Nicolas Dickgreber, Emily Brouwer, Pauline Tittmann, Florian Laenger, Danny Jonigk

Published in: Virchows Archiv | Issue 1/2021

Abstract

Chronic diffuse parenchymal lung disease (DPLD) is an umbrella term for a very heterogeneous group of lung diseases. Over the last decades, clinical, radiological and histopathological criteria have been established to define and separate these entities. More recently the clinical utility of this approach has been challenged as a unifying concept of pathophysiological mechanisms and a shared response to therapy across the disease spectrum have been described. In this review, we discuss molecular motifs for subtyping and the prediction of prognosis focusing on genetics and markers found in the blood, lavage and tissue. As a purely molecular classification so far lacks sufficient sensitivity and specificity for subtyping, it is not routinely used and not implemented in international guidelines. However, a better molecular characterization of lung disease with a more precise identification of patients with, for example, a risk for rapid disease progression would facilitate more accurate treatment decisions and hopefully contribute to better patients’ outcomes.

Länger F, Stark H, Braubach P, Ackermann M, Hussein K, Teiken K et al (2018) Injury patterns in interstitial lung diseases. Pathol. 39(Suppl 2):262–271

Noble PW, Homer RJ (2005) Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 33(2):113–120PubMed

(2000) American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 161(2 Pt 1):646–664

American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 165(2):277–304

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King te Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 183(6):788–824PubMedPubMedCentral

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC, American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society (2018) Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 198(5):e44–e68PubMed

De Sadeleer LJ, Meert C, Yserbyt J, Slabbynck H, Verschakelen JA, Verbeken EK et al (2018) Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: a retrospective observational study of 938 cases. Chest. 153(6):1416–1423PubMed

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr (2016) Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 47(1):243–253PubMedPubMedCentral

King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 370(22):2083–2092PubMed

10.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 370(22):2071–2082PubMed

11.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V (2020) Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 8(2):147–157PubMed

12.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y et al (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381(18):1718–1727PubMed

13.

Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L et al (2020) Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8(5):453–460

14.

Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M et al (2018) Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev Off J Eur Respir Soc. 31:27(150)

15.

Wijsenbeek M, Cottin V (2020) Spectrum of Fibrotic Lung Diseases. N Engl J Med 383(10):958–968PubMed

16.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, IPF Consensus Working Group et al (2019) Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what’s in a name? Eur Respir J 53(2):1801939

17.

Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R et al (2020) The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 55(6):2000085PubMedPubMedCentral

18.

Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, Aziz N, Kaminski N, Zlotnik A (2006) Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 173(2):188–198PubMed

19.

Pankratz DG, Choi Y, Imtiaz U, Fedorowicz GM, Anderson JD, Colby TV, Myers JL, Lynch DA, Brown KK, Flaherty KR, Steele MP, Groshong SD, Raghu G, Barth NM, Walsh PS, Huang J, Kennedy GC, Martinez FJ (2017) Usual interstitial pneumonia can be detected in transbronchial biopsies using machine learning. Ann Am Thorac Soc. 14(11):1646–1654PubMed

20.

Raghu G, Flaherty KR, Lederer DJ, Lynch DA, Colby TV, Myers JL, Groshong SD, Larsen BT, Chung JH, Steele MP, Benzaquen S, Calero K, Case AH, Criner GJ, Nathan SD, Rai NS, Ramaswamy M, Hagmeyer L, Davis JR, Gauhar UA, Pankratz DG, Choi Y, Huang J, Walsh PS, Neville H, Lofaro LR, Barth NM, Kennedy GC, Brown KK, Martinez FJ (2019) Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med. 7(6):487–496PubMed

21.

Jonigk D, Stark H, Braubach P, Neubert L, Shin H, Izykowski N, Welte T, Janciauskiene S, Warnecke G, Haverich A, Kuehnel M, Laenger F (2019) Morphological and molecular motifs of fibrosing pulmonary injury patterns. J Pathol Clin Res. 5(4):256–271PubMedPubMedCentral

22.

Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA (2009) Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PloS One. 4(4):e5134PubMedPubMedCentral

23.

Planas-Cerezales L, Arias-Salgado EG, Buendia-Roldán I, Montes-Worboys A, López CE, Vicens-Zygmunt V, Hernaiz PL, Sanuy RL, Leiro-Fernandez V, Vilarnau EB, Llinás ES, Sargatal JD, Abellón RP, Selman M, Molina-Molina M (2019) Predictive factors and prognostic effect of telomere shortening in pulmonary fibrosis. Respirol Carlton Vic. 24(2):146–153

24.

Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, Sciurba F, Dauber J, Selman M, Gochuico BR, Kaminski N (2008) MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 5(4):e93PubMedPubMedCentral

25.

White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR et al (2016) Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 194(10):1242–1251PubMedPubMedCentral

26.

Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF (2012) Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 185(1):67–76PubMedPubMedCentral

27.

Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS (2013) Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 143(5):1422–1429PubMed

28.

Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S et al (2020) Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest 158(2):646–659

29.

Hamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N, Kohno N (2016) Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers. 2016:1–8

30.

Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J, Costabel U (2014) Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med. 108(7):1031–1039PubMed

31.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG (2017) An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 5(12):946–955PubMed

32.

Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR (2018) Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir Med. 6(8):615–626PubMed

33.

Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR et al (2009) Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 179(8):717–723PubMed

34.

Cai M, Bonella F, He X, Sixt SU, Sarria R, Guzman J, Costabel U (2013) CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir Med. 107(9):1444–1452PubMed

35.

Invernizzi R, Barnett J, Rawal B, Nair A, Ghai P, Kingston S et al (2020) Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. Eur Respir J 55(4):1901519

36.

Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji W, Cookson WOC et al (2017) Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res 18(1):29PubMedPubMedCentral

37.

Prasse A, Binder H, Schupp JC, Kayser G, Bargagli E, Jaeger B, Hess M, Rittinghausen S, Vuga L, Lynn H, Violette S, Jung B, Quast K, Vanaudenaerde B, Xu Y, Hohlfeld JM, Krug N, Herazo-Maya JD, Rottoli P, Wuyts WA, Kaminski N (2019) BAL Cell gene expression is indicative of outcome and airway basal cell involvement in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 199(5):622–630PubMedPubMedCentral

38.

Walsh SLF (2018) Imaging biomarkers and staging in IPF. Curr Opin Pulm Med. 24(5):445–452PubMed

39.

Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA 3rd, Sporn TA, McAdams H, Schwarz MI, Schwartz DA (2005) Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 172(9):1146–1152PubMedPubMedCentral

40.

Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE et al (2011) A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 364(16):1503–1512PubMedPubMedCentral

41.

Borie R, Le Guen P, Ghanem M, Taillé C, Dupin C, Dieudé P et al (2019) The genetics of interstitial lung diseases. Eur Respir Rev Off J Eur Respir Soc. 30:28(153)

42.

Mathai SK, Pedersen BS, Smith K, Russell P, Schwarz MI, Brown KK et al (2016) Desmoplakin variants are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 193(10):1151–1160PubMedPubMedCentral

43.

Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, Guillen-Guio B, Ma SF, Okamoto T, John AE, Obeidat M, Yang IV, Henry A, Hubbard RB, Navaratnam V, Saini G, Thompson N, Booth HL, Hart SP, Hill MR, Hirani N, Maher TM, McAnulty R, Millar AB, Molyneaux PL, Parfrey H, Rassl DM, Whyte MKB, Fahy WA, Marshall RP, Oballa E, Bossé Y, Nickle DC, Sin DD, Timens W, Shrine N, Sayers I, Hall IP, Noth I, Schwartz DA, Tobin MD, Wain LV, Jenkins RG (2017) Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med. 5(11):869–880PubMedPubMedCentral

44.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T et al (2019) Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 200(2):199–208PubMedPubMedCentral

45.

Allen RJ, Guillen-Guio B, Oldham JM, Ma S-F, Dressen A, Paynton ML et al (2020) Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 201(5):564–574PubMedPubMedCentral

46.

Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, Batra K, Torrealba J, Garcia CK, Wolters PJ (2017) The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 5(8):639–647PubMedPubMedCentral

47.

Juge P-A, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S et al (2018) MUC5B Promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 379(23):2209–2219PubMedPubMedCentral

48.

Peljto AL, Zhang Y, Fingerlin TE, Ma S-F, Garcia JGN, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA (2013) Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 309(21):2232–2239PubMedPubMedCentral

49.

Oldham JM, Ma S-F, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, Huang Y, Strek ME, Noth I, IPFnet Investigators (2015) TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 192(12):1475–1482PubMedPubMedCentral

50.

Armanios M, Alder JK, Parry EM, Karim B, Strong MA, Greider CW (2009) Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet. 85(6):823–832PubMedPubMedCentral

51.

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL (2018) Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respir Med. 6(8):603–614PubMedPubMedCentral

52.

Swaminathan AC, Neely ML, Frankel CW, Kelly FL, Petrovski S, Durheim MT, Bush E, Snyder L, Goldstein DB, Todd JL, Palmer SM (2019) Lung transplant outcomes in patients with pulmonary fibrosis with telomere-related gene variants. Chest. 156(3):477–485PubMed

53.

Ley B, Torgerson DG, Oldham JM, Adegunsoye A, Liu S, Li J et al (2019) Rare protein-altering telomere-related gene variants in patients with chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med 200(9):1154–1163PubMedPubMedCentral

54.

Juge P-A, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L et al (2017) Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 49(5):1602314

55.

Yang IV, Burch LH, Steele MP, Savov JD, Hollingsworth JW, McElvania-Tekippe E, Berman KG, Speer MC, Sporn TA, Brown KK, Schwarz MI, Schwartz DA (2007) Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med. 175(1):45–54PubMed

56.

Kim SY, Diggans J, Pankratz D, Huang J, Pagan M, Sindy N, Tom E, Anderson J, Choi Y, Lynch DA, Steele MP, Flaherty KR, Brown KK, Farah H, Bukstein MJ, Pardo A, Selman M, Wolters PJ, Nathan SD, Colby TV, Myers JL, Katzenstein ALA, Raghu G, Kennedy GC (2015) Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med. 3(6):473–482PubMed

57.

Sivakumar P, Thompson JR, Ammar R, Porteous M, McCoubrey C, Cantu E et al (2019) RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation. ERJ Open Res 5(3):00117–2019

58.

McDonough JE, Ahangari F, Li Q, Jain S, Verleden SE, Herazo-Maya J et al (2019) Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight. 14:4(22)

59.

Yang IV, Coldren CD, Leach SM, Seibold MA, Murphy E, Lin J, Rosen R, Neidermyer AJ, McKean DF, Groshong SD, Cool C, Cosgrove GP, Lynch DA, Brown KK, Schwarz MI, Fingerlin TE, Schwartz DA (2013) Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax. 68(12):1114–1121PubMedPubMedCentral

60.

Patel NM, Kawut SM, Jelic S, Arcasoy SM, Lederer DJ, Borczuk AC (2013) Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. Eur Respir J. 41(6):1324–1330PubMedPubMedCentral

61.

Ackermann M, Stark H, Neubert L, Schubert S, Borchert P, Linz F et al (2020) Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases. Eur Respir J 55(3):1900933

62.

Vukmirovic M, Kaminski N (2018) Impact of transcriptomics on our understanding of pulmonary fibrosis. Front Med. 5:87

63.

Morse C, Tabib T, Sembrat J, Buschur KL, Bittar HT, Valenzi E et al (2019) Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J 54(2):1802441

64.

Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, Kaminski N (2007) Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PloS One. 2(5):e482PubMedPubMedCentral

65.

Tomassetti S, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G et al (2020) Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study. Lancet Respir Med. 8(8):786–794PubMed

66.

Courtwright AM, El-Chemaly S (2019) Telomeres in interstitial lung disease: the short and the long of it. Ann Am Thorac Soc. 16(2):175–181PubMedPubMedCentral

67.

Wiertz IA, Moll SA, Seeliger B, Barlo NP, van der Vis JJ, Korthagen NM et al (2020) Genetic variation in CCL18 gene influences CCL18 expression and correlates with survival in idiopathic pulmonary fibrosis: Part A. J Clin Med. 21:9(6)

68.

Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux M-L et al (2018) Idiopathic pulmonary fibrosis: prospective, case-controlled study of natural history and circulating biomarkers. Chest. 154(6):1359–1370PubMed

69.

Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H et al (2019) Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 20(1):227PubMedPubMedCentral

70.

Meyer KC, Raghu G (2011) Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J. 38(4):761–769PubMed

71.

Adderley N, Humphreys CJ, Barnes H, Ley B, Premji ZA, Johannson KA (2020) Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis. Eur Respir J 56(2):2000206

72.

Molyneaux PL, Cox MJ, Willis-Owen SAG, Mallia P, Russell KE, Russell A-M, Murphy E, Johnston SL, Schwartz DA, Wells AU, Cookson WO, Maher TM, Moffatt MF (2014) The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 190(8):906–913PubMedPubMedCentral

73.

Kitsios GD, Rojas M, Kass DJ, Fitch A, Sembrat JC, Qin S et al (2018) Microbiome in lung explants of idiopathic pulmonary fibrosis: a case-control study in patients with end-stage fibrosis. Thorax. 73(5):481–484PubMed

74.

Becker A, Vella G, Galata V, Rentz K, Beisswenger C, Herr C et al (2019) The composition of the pulmonary microbiota in sarcoidosis - an observational study. Respir Res. 20(1):46PubMedPubMedCentral

75.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ (2018) What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 51(5):1800692PubMed

76.

De Sadeleer LJ, Goos T, Yserbyt J, Wuyts WA (2020) Towards the essence of progressiveness: bringing progressive fibrosing interstitial lung disease (PF-ILD) to the next stage. J Clin Med. 9(6):1722PubMedCentral

Title: Molecular approach to the classification of chronic fibrosing lung disease—there and back again
Authors: Stijn E. Verleden
Peter Braubach
Mark Kuehnel
Nicolas Dickgreber
Emily Brouwer
Pauline Tittmann
Florian Laenger
Danny Jonigk
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: Idiopathic Pulmonary Fibrosis
Biomarkers
Published in: Virchows Archiv / Issue 1/2021
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-020-02964-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular approach to the classification of chronic fibrosing lung disease—there and back again

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

The pulmonary pathology of COVID-19

Molecular pathology of thymomas: implications for diagnosis and therapy

Challenges in lung and thoracic pathology

Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus

Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors

Morphologic and molecular classification of lung neuroendocrine neoplasms